Novo Nordisk (NVO) Stock Drops 15% After CagriSema Fails to Beat Eli Lilly’s Zepbound

TLDR Novo Nordisk stock fell 15% after CagriSema failed to prove non-inferiority to Eli Lilly’s tirzepatide in an 84-week trial. CagriSema delivered 23% weight loss vs. 25.5% for tirzepatide — missing its primary endpoint. The stock hit its lowest level since June 2021, down nearly 50% over the past year. Novo’s CEO remains confident in [...]

The post Novo Nordisk (NVO) Stock Drops 15% After CagriSema Fails to Beat Eli Lilly’s Zepbound appeared first on Blockonomi.